Showing 2251-2260 of 8785 results for "".
ISDPA: Dr. Lio on Alternative and Innovative Approaches
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-lio-alternative-and-innovative-approaches/27066/Practical Dermatology Editorial Board member Peter Lio, MD, discusses the presentation that he and Tracee Blackburn, PA-C, gave about alternative and innovative approaches in dermatology, as well as the importance of educational engagement between physician assistants and dermatologists, at the IlliNoah Worcester 2024: Dr. Bhatia on Actinic Keratosis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bhatia-actinic-keratosis/24585/Neal Bhatia, MD, FAAD, summarizes his lecture on actinic keratosis and photodynamic therapy at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: Birch Triterpenes Gel Gets FDA Approval for EB, VTE Risk is Lower in Patients with AD, and Are Topical Steroids Affecting Bone Health?
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-birch-triterpenes-t-gel-gets-fda-approval-for-eb-vte-risk-is-lower-in-patients-with-ad-and-are-topical-steroids-affecting-bone-health/20233/A birch bark extract topical from Chiesi Global Rare Diseases represents the latest in treatment approvals for epidermolysis bullosa. Patients with atopic dermatitis may have a decreased risk for developing venous thromboembolism. Commonly prescribed topical steroids may raise some patients' risk foASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeHow does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.Roflumilast Cream, 0.15%, for Atopic Dermatitis
https://practicaldermatology.com/issues/december-2024/Roflumilast-Cream-Atopic-Dermatitis/32840/Atopic dermatitis (AD) is a chronic, persistent inflammatory condition that significantly disrupts the quality of life of patients diagnosed with it. Moreover, AD presents challenges for clinicians when counseling patients on the management of their condition. Application frequency, treatment formulChoosing the Right Wound Dressing
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/choosing-the-right-wound-dressing/33017/Dennis Orgill, MD, PhD, a reconstructive plastic surgeon at Brigham and Women's Hospital in Boston, discusses the importance of choosing the right dressing for wound care at Masterclasses in Dermatology 2025 in Sarasota.Noah Worcester 2024: Dr. Greenberg on the Society
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-greenberg-society/24588/Michael Greenberg, MD, president of the Noah Worcester Dermatological Society, speaks at the organization’s 2024 meeting about what makes the event special.Cutaneous Oncology in 2024
https://practicaldermatology.com/conferences/maui-derm-2024/cutaneous-oncology-in-2024/20266/Resident Of Distinction Award-winner Banu Farabi, MD, a PGY-3 resident at New York Medical College, talks about a review she attended highlighting the latest therapeutic approaches to treating conditions such as actinic keratosis and several different types of skin cancer, as well as an overview ofNew FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.